2025.05. 24 本文字数：2099，阅读时长大约3分钟 Wind数据显示，在已经披露2024年年报的药企中，高管年薪在千万以上绝非个例。在俞德超之前， 还有多家药企的高管薪酬过亿。 作者 | 第一财经 陈敏之 近日，理想汽车（02015.HK/LI.US）创始人、董事长兼CEO李想2024年领取6.39亿元"天价年薪"冲 上热搜引发热议。 事实上，创新药企业里，也不乏上亿年薪的创始人和CEO，但有所不同的是，这些创新药公司多数 还没有走完商业化历程，公司处于连年亏损状态。比如刚刚敲钟上市的映恩生物（9606.HK），创 始人朱忠远去年薪酬8556万元，公司同期亏损超过10亿元。近期三次递表港交所的英矽智能，执行 董事任峰2024年薪酬总计307.3万美元，公司当年净亏损1709.6万美元。 这样例子在创新药企业里比比皆是。Wind数据显示，思路迪医药股份（1244.HK）董事长龚兆龙 2024年的薪酬为2067万元，六年的薪酬总额则超过5亿元，而公司六年亏损超40亿元。 高薪背后，是创新药行业整体尚未步出资本寒冬。高管的收入与公司业绩形成的强烈反差，引发市场 对行业价值导向的深度思考。 年薪千万比比皆 ...

Group 1 - The article highlights the stark contrast between high executive salaries and the financial performance of companies in the innovative drug sector, where many firms are still unprofitable [2][10][11] - Li Xiang, the founder and CEO of Li Auto, received a salary of 639 million RMB in 2024, sparking discussions about excessive executive compensation in the context of ongoing company losses [2][3] - Companies like InnoCare Pharma and Sihuan Pharmaceutical have reported significant executive salaries while simultaneously posting substantial losses, raising questions about the sustainability of such compensation structures [5][10] Group 2 - The article provides examples of high executive salaries in the innovative drug industry, including Zhu Zhongyuan of InnoCare Pharma with a salary of 85.56 million RMB in 2024, despite the company losing over 1 billion RMB [3][10] - Other notable salaries include Yu Dechao of Innovent Biologics, who earned approximately 136 million RMB, and Gong Zhaolong of Sihuan Pharmaceutical, whose total compensation exceeded 500 million RMB over six years [5][10] - The trend of high salaries persists even among companies that have not yet commercialized their products, such as Yingxi Intelligent and Weili Zhibo, which have reported significant losses [11]

Group 1 - The core viewpoint of the news is the performance and holdings of the Wanjiay Economic New Momentum Mixed C Fund, which has shown a decline in recent value but positive returns over longer periods [1] - As of May 23, 2025, the latest net value of the fund is 1.6007 yuan, reflecting a decrease of 1.79% [1] - The fund's one-month return is -4.46%, ranking 4362 out of 4480 in its category, while its six-month return is 22.90%, ranking 161 out of 4322, and its year-to-date return is 28.00%, ranking 90 out of 4372 [1] Group 2 - The top ten stock holdings of the Wanjiay Economic New Momentum Mixed C Fund account for a total of 75.95%, with significant positions in companies such as Ruixin Micro (9.12%), BeiGene-U (8.80%), and Deepin Technology (8.64%) [1] - The fund was established on February 7, 2018, and as of March 31, 2025, it has a total scale of 1.223 billion yuan [1] - The fund manager, Huang Xingliang, has a strong academic background with a Ph.D. from Tsinghua University and extensive experience in the investment management industry [2]

中经记者 顾梦轩 夏欣 广州、北京报道 基金一季报显示，诺安精选价值基金的前十大重仓股分别是：科伦博泰生物-B、康方生物、信达生物、 和黄医药、新诺威、璟泽制药-U、益方生物-U、百济神州-U、百利天恒和诺诚健华-U。 谈及产品定位，唐晨在接受《中国经营报》记者专访时表示，诺安精选价值基金的定位主要在生物科技 领域，生物科技领域正在从过去的科研探索阶段快速向设计与应用阶段迈进，必然会产生很多产业级的 投资机会。"从产业周期的角度去研判，综合考虑技术的突破迭代与应用、产业融合重构与成熟，场景 的真实需求与趋势，最终选择了围绕创新药方向去构建。"唐晨表示。 市场各个方面反映亦逐步验证了唐晨的判断，医药板块产业进入收获期、政策进入红利期、市场主题得 到确立和演绎。"这个方向有行情是必然。"唐晨强调，医药板块以及创新药板块的行情发生在今年，是 各种催化因素共振的偶然，如果拉长时间维度，它反映的可能只是这轮产业周期的一小段。 谈及在基金季报中提到的"通过'寻找与时代相契合的超级大单品'来获取超额收益"背后的思考逻辑，唐 晨表示，"大单品"策略是股票市场上的经典策略之一，也是实业界的重要发展策略。不过，在"大单 品"之前 ...

Group 1 - The core viewpoint of the news highlights the approval of a new innovative drug by Heng Rui Medicine, which is the first self-developed DPP-4 inhibitor combined with metformin in China, aimed at improving blood sugar control for adult patients with type 2 diabetes [1] - Following the announcement, Heng Rui Medicine's stock surged nearly 30% in the Hong Kong market, indicating strong investor confidence in the innovative drug sector [1] - The Hong Kong innovative drug index has seen a significant decrease in its price-to-earnings ratio from 64 times on February 21 to 25 times on May 22, suggesting a favorable investment opportunity in the sector [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the National Index for Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs [2] - The larger innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from advancements in AI, the internationalization of domestic innovative drugs, and the introduction of new healthcare policies [2] - According to Xingye Securities, the innovative drug sector in China is transitioning from a "follower" to a "leader," with significant advancements expected in new targets and technologies by 2025, showcasing strong global competitiveness in areas like ADC, bispecific antibodies, and cell therapy [2]

Group 1 - The rise of ETF-FOF products is aimed at helping investors select suitable ETFs amidst a growing supply of ETF products, with several public fund institutions reporting such products this year [1] - The advantages of ETF-FOF products include higher capital efficiency, lower fees, and T+1 valuation disclosure, but they require enhanced macroeconomic research and asset allocation capabilities from public fund research teams [1] - The total issuance of science and technology innovation bonds in China's exchange bond market has reached 1.2 trillion yuan, with a significant increase in the number of strategic emerging industry companies listed [1] Group 2 - Securities firms are experiencing a new round of interest rate cuts, with customer margin interest rates dropping to as low as 0.05%, following banks' reductions in deposit rates [2] - The number of merger and acquisition exits involving PE/VC institutions has increased, with a 7.8% year-on-year rise in the first quarter of this year [2] - Several steel companies are actively investing in non-oriented silicon steel, driven by strong demand from home appliances and electric vehicles, indicating a balanced supply-demand situation in the industry [2] Group 3 - The camping economy in China is projected to reach a core market size of 213.97 billion yuan in 2024, with a year-on-year growth of 60.4%, and is expected to grow to 487.98 billion yuan by 2030 [3] - The price of polysilicon is stabilizing after a previous decline, with expectations that it will maintain its current price range for some time [4] - The global interest in small molecule drugs is increasing, with major pharmaceutical companies investing heavily in this area, indicating a competitive landscape for drug development [4] Group 4 - EV Electra plans to invest 1 billion USD in the restructuring of high-end automotive company, committing to a minimum of 100,000 vehicles or 3 billion USD in overseas procurement orders over the next three years [5] - Apple is reportedly planning to launch smart glasses by the end of 2026, aiming to capture a share of the AI device market [6] - Google is under investigation by the U.S. Department of Justice regarding its AI technology agreements, which may potentially violate antitrust laws [6]

智通财经APP获悉，截止5月22日收盘，有88只股票创52周新高，其中名仕快相(08483)、茂盛控股 (00022)、帝王实业控股(01950)创高率位于前3位，分别为67.60%、46.55%、45.71%。 | 南方东英越南３０ | 6.690 | 6.690 | 0.22% | | --- | --- | --- | --- | | (03004) | | | | | 诺诚健华(09969) | 10.960 | 11.320 | 0.18% | | 港灯－ＳＳ(02638) | 5.680 | 5.680 | 0.18% | | ESR(01821) | 12.860 | 12.860 | 0.16% | | 招商局港口(00144) | 14.320 | 14.460 | 0.14% | | 紫金矿业(02899) | 18.580 | 18.980 | 0.12% | | Ａ博时人民币－Ｒ | 1,059.000 | 1,059 | 0.05% | | (83192) | | | | | 工银南方国债(03199) | 115.400 | 115.400 | 0.04% | | Ａ博时港元(03 ...

Group 1 - The Hong Kong Innovation Drug ETF (159567) has experienced a year-to-date increase of 36.43% as of May 21, indicating strong performance in the biotech sector [2] - The ETF closely tracks the Hong Kong Stock Connect Innovation Drug Index (987018), which reflects the operational characteristics of listed biotech companies in Hong Kong [2] - The approval of China's first cross-border segmented production pilot project for innovative biological products marks a significant milestone, with Johnson & Johnson's drug being the first to receive such approval [2] Group 2 - Donghai Securities highlights that China's innovative drugs have advantages in low R&D costs and high efficiency, positioning the country as a potential center for low-cost R&D and production [2] - The transition from "generic following" to "innovation leading" is expected to accelerate, with multinational pharmaceutical companies seeking to reduce R&D and production costs under stricter pricing systems [2] - The CXO industry chain in China is likely to further solidify its market position as a result of these developments [2] Group 3 - According to Founder Securities, the systematic valuation uplift in the innovative drug sector is driven by the recognition of the business models of Chinese innovative drug companies [3] - Leading companies are entering profitability phases, and their R&D pipelines are beginning to generate regular income through business development (BD) [3] - The market is starting to assign more valuation premiums to drug companies' innovative pipelines, indicating a shift towards systematic valuation increases [3]

Group 1 - Heng Rui Medicine has set the final price for its H-share issuance at HKD 44.05 per share, with expected listing on May 23, 2025 [1] - Vanke A has signed a borrowing contract with Shenzhen Metro Group for RMB 4.2 billion, using up to RMB 6 billion of Wanwu Cloud stock as collateral [2] - Longqi Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international competitiveness [3] Group 2 - Shanghai Laishi's controlling shareholder, Haiyingkang, plans to increase its stake in the company by investing between RMB 250 million and RMB 500 million [4] - Wangzi New Materials' controlling shareholder sold 1.11 million shares, accounting for 0.29% of the total share capital, amid the "controlled nuclear fusion" concept [5] - Huashi Technology's actual controller, Ye Jianbiao, has had his detention extended by three months, but the company's operations remain normal [6] Group 3 - Sichuan Gold's major shareholders plan to reduce their stakes by 2.5% and 3% respectively, citing personal funding needs [7] - Naxinwei has set the inquiry transfer price at RMB 163.15 per share, with full subscription from institutional investors [8] - Zhejiang Rongtai plans to invest RMB 20 million to establish a wholly-owned subsidiary focused on robotics [9] Group 4 - Kingood Co. has received a notification from a global leading automaker for a wheel product project in the U.S., with an estimated sales amount of approximately USD 158 million over five years [10] - Shanghai Xiba plans to purchase patents for hydrogen-electric hybrid power systems and solid-state lithium-ion battery technology, investing a total of RMB 25 million [11] - Nocare Biopharma's application for the market approval of Tafasitamab for treating relapsed/refractory DLBCL has been approved, marking a significant milestone in the market [12]

Core Insights - Nuo Cheng Jian Hua reported a revenue of 381 million yuan for Q1 2025, representing a year-on-year growth of 129.92%, with a net profit of 14 million yuan, up 109.94% year-on-year [2] - The company's gross margin improved by 5.1 percentage points to 90.5% compared to the same period last year [2] - The main driver of revenue growth is the commercialization of the drug Acalabrutinib, which generated 310 million yuan in revenue during the reporting period, an increase of 89.2% [2] Product Development - Acalabrutinib was approved for first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in China on April 25, 2023, expanding its market potential [2][6] - The drug has already been included in the national medical insurance for multiple indications, which is expected to further boost sales [2] - The company is also advancing its pipeline with Tafasitamab, a CD19 monoclonal antibody, which has been approved for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) [3][9] Market Potential - CLL accounts for approximately 3% of adult leukemia cases in China, with about 7,500 new patients diagnosed annually [5] - The approval of Acalabrutinib for first-line treatment is anticipated to significantly enhance treatment options for patients and drive company growth [6] - The market for Tafasitamab is projected to exceed 1.5 billion yuan in peak sales under optimistic scenarios [10] Competitive Landscape - Acalabrutinib is positioned as a potential best-in-class BTK inhibitor, with superior selectivity and safety profile compared to existing competitors [7][8] - The company faces competition from other approved therapies targeting similar indications, particularly in the relapsed or refractory settings [6] Financial Health - Nuo Cheng Jian Hua reported a strong cash position of approximately 7.78 billion yuan as of the end of Q1 2025, which will support ongoing clinical trials and research investments [8]